Last reviewed 2026-04-19 · How we verify
PD-1-M1-NK Cells, developed by Jiuwei Cui, is an investigational therapy for advanced gastric and colorectal cancer. Currently in Phase 1, it leverages NK cells to target PD-1, aiming to enhance immune response against tumors.
No approved indications tracked.
No common side effects on file.